IOVANCE BIOTHERAPEUTICS

Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors.

#SimilarOrganizations #People #Financial #Website #More

IOVANCE BIOTHERAPEUTICS

Social Links:

Facebook

Industry:

Biotechnology Health Care Medical

Founded:

2007-01-01

Address:

New York, New York, United States

Country:

United States

Website Url:

http://www.iovance.com

Total Employee:

251+

Status:

Active

Contact:

(212)946-4856

Total Funding:

1.22 B USD

Technology used in webpage:

IPv6 GoDaddy DNS COVID-19 Akamai Hosted Rackspace

Similar Organizations

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

cel-sci-logo

CEL-SCI

CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.

elicio-therapeutics-logo

Elicio Therapeutics

Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.

gracell-biotechnologies-logo

Gracell Biotechnologies

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.

harpoon-therapeutics-logo

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.

Current Employees Featured

igor-bilinsky_image

Igor Bilinsky
Igor Bilinsky Chief Operating Officer @ Iovance Biotherapeutics
Chief Operating Officer
2021-03-01

not_available_image

John Schick
John Schick Vice President, Market Access & Policy, Cell Therapy @ Iovance Biotherapeutics
Vice President, Market Access & Policy, Cell Therapy
2020-05-01

sandy-mohan_image

Sandy Mohan
Sandy Mohan Vice President, Quality @ Iovance Biotherapeutics
Vice President, Quality
2019-09-01

not_available_image

Timothy E. Morris
Timothy E. Morris Chief Financial Officer @ Iovance Biotherapeutics
Chief Financial Officer

maria-fardis_image

Maria Fardis
Maria Fardis President & Chief Executive Officer @ Iovance Biotherapeutics
President & Chief Executive Officer
2016-06-01

Founder

manish-singh_image

Manish Singh

Stock Details

Company's stock symbol is NASDAQ:IOVA

Acquisitions List

Date	Company	Article	Price
2013-10-31	Genesis Biopharma	Genesis Biopharma acquired by Iovance Biotherapeutics	N/A

Investors List

orbimed-advisors_image

Official Site Inspections

http://www.iovance.com Semrush global rank: 616.87 K Semrush visits lastest month: 72.59 K

Host Informations
Whois Informations

Loading ...